CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer is a phase 1/2 interventional study registered as NCT07322094 by TORL Biotherapeutics, LLC, with 60 participants planned, started 2025-12-10 and due to reach its primary completion in 2027-12. Interventions recorded: TORL-1-23 and paclitaxel, TORL-1-23 and carboplatin, TORL-1-23, paclitaxel, and carboplatin. Conditions listed: FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.